← Leaderboards
Jelena Levi
University Of California, San Francisco
$3,265,839
Attributed
$5,660,416
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,660,416 · 3
By mechanism
R44$2,912,239 · 2
R01$2,748,177 · 1
Top collaborators
- Youngho Seo4 shared
- Samuel Ray Goth2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Jason G. Cyster$29,153,268
- Hideho Okada$20,052,698
- Mark S Anderson$96,401,564
- Valerie Marie Weaver$26,171,723
- Mehrdad Matloubian$1,809,475
Others in their field
Other Emerging Leaders on “Biological Markers”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,644,754
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,375,181
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,483,553
- Leonard Freedmand · Leidos Biomedical Research, Inc.$64,555,721
- Yunda Huang · Fred Hutchinson Cancer Center$54,118,126
- Susan Abushakra · Alzheon, Inc.$50,765,244
Research focus
Biological MarkersPositron-Emission TomographySignal TransductionImmunotherapyBloodImageDetectionImmune Checkpoint InhibitorUptakeCheckpoint TherapyMonitorCancer TypeCancer PatientComparativeImaging TechniquesImaging ApproachImaging ModalityFunctional DisorderHeartImaging BiomarkerCardiacCombinatorialCardiac MyocytesCancer Imaging
Grant awards (7)
Imaging intracerebral and systemic T cell immunity in patients with Alzheimer's disease using 18F-F-AraG$871,261
R44 · FY2025 · AG · contact PI
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$658,891
R01 · FY2025 · HL
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$666,104
R01 · FY2024 · HL
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$694,766
R01 · FY2023 · HL
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$728,416
R01 · FY2022 · HL
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer$1,020,835
R44 · FY2018 · CA · contact PI
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer$1,020,143
R44 · FY2017 · CA · contact PI